Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nouf Alluqmani

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Molecular Therapy Oncolytics|May 16, 2022
Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapyBoaz Wong, Anabel Bergeron, Nouf Alluqmani, et al.
Frontiers in Immunology|December 19, 2022
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokinesNouf Alluqmani, Anna Jirovec, Zaid Taha, et al.
Nature Communications|August 19, 2018
Galectin-9 binds IgM-BCR to regulate B cell signalingAnh Cao, Nouf Alluqmani, Fatima Hifza Mohammed Buhari, et al.
Communications Biology|May 24, 2020
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergyRozanne Arulanandam, Zaid Taha, Vanessa Garcia, et al.
Frontiers in Immunology|May 8, 2023
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirusZaid Taha, Mathieu J F Crupi, Nouf Alluqmani, et al.
Molecular Therapy. Methods & Clinical Development|October 12, 2023
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Rida Gill, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2021
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entryTaha Azad, Ragunath Singaravelu, Zaid Taha, et al.
Frontiers in Immunology|January 30, 2023
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOXJack T Whelan, Ragunath Singaravelu, Fuan Wang, et al.
Frontiers in Immunology|November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancerMathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Nature Communications|August 23, 2024
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapyZaid Taha, Mathieu Joseph François Crupi, Nouf Alluqmani, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Molecular Therapy Oncolytics|May 16, 2022
Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapyBoaz Wong, Anabel Bergeron, Nouf Alluqmani, et al.
Frontiers in Immunology|December 19, 2022
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokinesNouf Alluqmani, Anna Jirovec, Zaid Taha, et al.
Nature Communications|August 19, 2018
Galectin-9 binds IgM-BCR to regulate B cell signalingAnh Cao, Nouf Alluqmani, Fatima Hifza Mohammed Buhari, et al.
Communications Biology|May 24, 2020
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergyRozanne Arulanandam, Zaid Taha, Vanessa Garcia, et al.
Frontiers in Immunology|May 8, 2023
Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirusZaid Taha, Mathieu J F Crupi, Nouf Alluqmani, et al.
Molecular Therapy. Methods & Clinical Development|October 12, 2023
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Rida Gill, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2021
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entryTaha Azad, Ragunath Singaravelu, Zaid Taha, et al.
Frontiers in Immunology|January 30, 2023
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOXJack T Whelan, Ragunath Singaravelu, Fuan Wang, et al.
Frontiers in Immunology|November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancerMathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Nature Communications|August 23, 2024
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapyZaid Taha, Mathieu Joseph François Crupi, Nouf Alluqmani, et al.
Pageof 2